Vol 3, No 4 (2010)
Prace poglądowe
Published online: 2010-12-30
Choroby układu sercowo-naczyniowego u pacjentów po zabiegu transplantacji nerki
Forum Nefrologiczne 2010;3(4):260-271.
Abstract
Choroby układu sercowo-naczyniowego są najsilniejszym
predyktorem zgonu u pacjentów z przewlekłą
chorobą nerek oraz u chorych po zabiegu
transplantacji nerki. Te dwie grupy pacjentów uważa
się za populacje charakteryzujące się wyjątkowo
wysokim ryzykiem powikłań sercowo-naczyniowych.
Z drugiej strony upośledzenie funkcji nerek
uważa się także za czynnik ryzyka powikłań
sercowo-naczyniowych. Postępowanie w przypadku
tych powikłań jest wyzwaniem dla lekarzy
zajmujących się pacjentami z przewlekłą chorobą
nerek i po zabiegu transplantacji nerki. W pracy przedstawiono główne czynniki ryzyka powikłań
sercowo-naczyniowych u biorców przeszczepu
nerkowego oraz kwalifikację kardiologiczną potencjalnych
biorców przeszczepu nerki. Omówiono
także główne problemy ze strony układu sercowonaczyniowego
po zabiegu transplantacji nerki,
ostry zespół wieńcowy, cukrzycę potransplantacyjną,
nadciśnienie tętnicze oraz zaburzenia gospodarki
lipidowej.
Forum Nefrologiczne 2010, tom 3, nr 4, 260-271
Forum Nefrologiczne 2010, tom 3, nr 4, 260-271
Keywords: transplantacja nerekcukrzyca potransplantacyjnanadciśnienie tętniczepowikłania sercowo-naczyniowePCICABGdyslipidemiachoroba niedokrwienna serca
References
- Hill MN, Grossman RA, Feldman HI, et al. Changes in causes of death after renal transplantation, 1966 to 1987. Am J Kidney Dis. 1991; 17(5): 512–518.
- Yeo FE, Villines TC, Bucci JR, et al. Cardiovascular risk in stage 4 and 5 nephropathy. Adv Chronic Kidney Dis. 2004; 11(2): 116–133.
- Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation. 2006; 82(5): 603–611.
- US Renal Data System: USDRS 2009 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2009.
- Kasiske BL, Guijarro C, Massy ZA, et al. Serum albumin and mortality after renal transplantation. Am J Kidney Dis. 1996; 27(1): 117–123.
- Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108(17): 2154–2169.
- de Mattos AM, Prather J, Olyaei AJ, et al. Cardiovascular events following renal transplantation: role of traditional and transplant-specific risk factors. Kidney Int. 2006; 70(4): 757–764.
- Kiberd B, Panek R. Cardiovascular outcomes in the outpatient kidney transplant clinic: the Framingham risk score revisited. Clin J Am Soc Nephrol. 2008; 3(3): 822–828.
- Sarnak MJ, Levey AS, Schoolwerth AC, et al. American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation. 2003; 108(17): 2154–2169.
- Collins AJ, Li S, Gilbertson DT, et al. Chronic kidney disease and cardiovascular disease in the Medicare population. Kidney Int. Kidney Int. 2003; Supl.(87): 24–31.
- Sarnak M, Levey A. Epidemiology of Cardiac Disease in Dialysis Patients. Seminars in Dialysis. 1999; 12(2): 69–76.
- Culleton BF, Larson MG, Wilson PW, et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int. 1999; 56(6): 2214–2219.
- Levey AS, Eknoyan G. Cardiovascular disease in chronic renal disease. Nephrol Dial Transplant. 1999; 14(4): 828–833.
- Zoccali C, Mallamaci F, Tripepi G. Traditional and emerging cardiovascular risk factors in end-stage renal disease. Kidney Int Suppl. 2003(85): S105–S110.
- Longenecker JC, Coresh J, Powe NR, et al. Traditional cardiovascular disease risk factors in dialysis patients compared with the general population: the CHOICE Study. J Am Soc Nephrol. 2002; 13(7): 1918–1927.
- Bostom AG, Shemin D, Lapane KL, et al. Hyperhomocysteinemia, hyperfibrinogenemia, and lipoprotein (a) excess in maintenance dialysis patients: a matched case-control study. Atherosclerosis. 1996; 125(1): 91–101.
- Makita Z, Yanagisawa K, Kuwajima S, et al. The role of advanced glycosylation end-products in the pathogenesis of atherosclerosis. Nephrol Dial Transplant. 1996; 11 Suppl 5: 31–33.
- Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med. 1988; 84(6): 985–992.
- Gill JS, Ma I, Landsberg D, et al. Cardiovascular events and investigation in patients who are awaiting cadaveric kidney transplantation. J Am Soc Nephrol. 2005; 16(3): 808–816.
- Rosas SE, Mensah K, Weinstein RB, et al. Coronary artery calcification in renal transplant recipients. Am J Transplant. 2005; 5(8): 1942–1947.
- Hernández D, Rufino M, Bartolomei S, et al. Clinical impact of preexisting vascular calcifications on mortality after renal transplantation. Kidney Int. 2005; 67(5): 2015–2020.
- Port FK, Wolfe RA, Mauger EA, et al. Comparison of survival probabilities for dialysis patients vs cadaveric renal transplant recipients. JAMA. 1993; 270(11): 1339–1343.
- Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341(23): 1725–1730.
- Ojo AO, Hanson JA, Meier-Kriesche H, et al. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. J Am Soc Nephrol. 2001; 12(3): 589–597.
- Johnson JG, Gore SM, Firth J. The effect of age, diabetes, and other comorbidity on the survival of patients on dialysis: a systematic quantitative overview of the literature. Nephrol Dial Transplant. 1999; 14(9): 2156–2164.
- Miskulin DC, Athienites NV, Yan G, et al. Hemodialysis (HEMO) Study Group. Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial. Kidney Int. 2001; 60(4): 1498–1510.
- Vanrenterghem YFC, Claes K, Montagnino G, et al. Risk factors for cardiovascular events after successful renal transplantation. Transplantation. 2008; 85(2): 209–216.
- Jardine AG, Fellström B, Logan JO, et al. Cardiovascular risk and renal transplantation: post hoc analyses of the Assessment of Lescol in Renal Transplantation (ALERT) Study. Am J Kidney Dis. 2005; 46(3): 529–536.
- Kasiske BL, Chakkera HA, Roel J. Explained and unexplained ischemic heart disease risk after renal transplantation. J Am Soc Nephrol. 2000; 11(9): 1735–1740.
- Rigatto C, Parfrey P, Foley R, et al. Congestive heart failure in renal transplant recipients: risk factors, outcomes, and relationship with ischemic heart disease. J Am Soc Nephrol. 2002; 13(4): 1084–1090.
- Ducloux D, Motte G, Challier B, et al. Serum total homocysteine and cardiovascular disease occurrence in chronic, stable renal transplant recipients: a prospective study. J Am Soc Nephrol. 2000; 11(1): 134–137.
- Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation. 2003; 75(8): 1291–1295.
- Abbott KC, Yuan CM, Taylor AJ, et al. Early renal insufficiency and hospitalized heart disease after renal transplantation in the era of modern immunosuppression. J Am Soc Nephrol. 2003; 14(9): 2358–2365.
- Kiberd B, Keough-Ryan T, Panek R. Cardiovascular disease reduction in the outpatient kidney transplant clinic. Am J Transplant. 2003; 3(11): 1393–1399.
- Israni AK, Snyder JJ, Skeans MA, et al. PORT Investigators. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant. 2010; 10(2): 338–353.
- Alhamad T, Brennan DC, Brifkani Z, et al. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol. 2005; 16(2): 496–506.
- Kasiske BL, Maclean JR, Snyder JJ. Acute myocardial infarction and kidney transplantation. J Am Soc Nephrol. 2006; 17(3): 900–907.
- Brown JH, Murphy BG, Douglas AF, et al. Influence of immunosuppressive therapy on lipoprotein(a) and other lipoproteins following renal transplantation. Nephron. 1997; 75(3): 277–282.
- Holdaas H, Fellström B, Jardine AG, et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet. 2003; 361(9374): 2024–2031.
- Jardine AG, Holdaas H, Fellström B, et al. ALERT Study Investigators. fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT Study. Am J Transplant. 2004; 4(6): 988–995.
- März W, Genser B, Drechsler C, et al. German Diabetes and Dialysis Study Investigators, German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005; 353(3): 238–248.
- Fellström BC, Jardine AG, Schmieder RE, et al. AURORA Study Group. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009; 360(14): 1395–1407.
- Baigent C, Landry M. Study of Heart and Renal Protection (SHARP). Kidney Int Suppl. 2003(84): S207–S210.
- Schwenger V, Zeier M, Ritz E. Hypertension after renal transplantation. Curr Hypertens Rep. 2001; 3(5): 434–439.
- Olyaei AJ, deMattos AM, Bennett WM. A practical guide to the management of hypertension in renal transplant recipients. Drugs. 1999; 58(6): 1011–1027.
- Mancia G, De Backer G, Dominiczak A, et al. ESH-ESC Task Force on the Management of Arterial Hypertension. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens. 2007; 25(9): 1751–1762.
- Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009; 18: 308–347.
- Kidney Disease Outcomes Quality Initiative (K/DOQI). K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004; 43(5 Suppl 1): S1–S290.
- Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6): 1206–1252.
- Eknoyan G. National Kidney Foundation K/DOQI, National Kidney Foundation. Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39(2 Suppl 1): S1–S266.
- European best practice guidelines for renal transplantation. Nephrol Dial Transplant. 2002; 17(supl. 4): 1–25.
- www.renal.org/Clinical/GuidelinesSection/ /ComplicationsofCKD.aspx (16.10.2010).
- Kidney Disease: Improving Global Outcomes (KDIGO) plant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Trans. 2009; 9(supl. 3): S1–S157.
- Thuraisingham RC, Yaqoob MM. Blood pressure guidelines in chronic kidney disease: a critical review. Nephron Clin Pract. 2009; 113(4): c294–c300.
- Philipp T, Martinez F, Geiger H, et al. Candesartan improves blood pressure control and reduces proteinuria in renal transplant recipients: results from SECRET. Nephrol Dial Transplant. 2010; 25(3): 967–976.
- Lopau K, Wanner C. Hypertension after kidney transplantation: still a SECRET? Nephrol Dial Transplant. 2010; 25(3): 664–665.
- Kasiske BL, Snyder JJ, Gilbertson D, et al. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant. 2003; 3(2): 178–185.
- Madziarska K, Weyde W, Krajewska M, et al. The increased risk of post-transplant diabetes mellitus in peritoneal dialysis-treated kidney allograft recipients. Nephrol Dial Transplant. 2011; 26(4): 1396–1401.
- American CoA, Fleisher LA, Beckman JA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). Anesth Analg. 2008; 106: 685–712.
- Kasiske BL, Cangro CB, Hariharan S. The Evaluation of the Renal Transplant Candidates: Clinical Practice Guidelines. American Journal of Transplantation. 2001; 1(s2): 3–95.
- K/DOQI Workgroup. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients. Am J Kidney Dis. 2005; 45(4 Suppl 3): S1–S153.
- Knoll G, Cockfield S, Blydt-Hansen T, et al. Kidney Transplant Working Group of the Canadian Society of Transplantation, Kidney Transplant Working Group of the Canadian Society of Transplantation. Canadian Society of Transplantation: consensus guidelines on eligibility for kidney transplantation. CMAJ. 2005; 173(10): S1–25.
- Herzog CA, Ma JZ, Collins AJ. Long-term outcome of renal transplant recipients in the United States after coronary revascularization procedures. Circulation. 2004; 109(23): 2866–2871.
- Herzog CA. Acute myocardial infarction in patients with end-stage renal disease. Kidney Int Suppl. 1999; 71: S130–S133.
- Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant. 2005; 20(1): 167–175.
